Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Basil S Lewis

Showing results (191-200 of 240) with videos related to

Pageof 24
Sort By:
Circulation|May 28, 2009
Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial, John H Alexander, Richard C Becker, et al.
European Heart Journal|October 23, 2013
Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trialJohn H Alexander, Renato D Lopes, Laine Thomas, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|June 28, 2021
Subgroup analyses in randomized clinical trials: value and limitations. Review #3 on important aspects of randomized clinical trials in cardiovascular pharmacotherapyHeinz Drexel, Stuart J Pocock, Basil S Lewis, et al.
Neurology|March 1, 2019
Effects of blood pressure and lipid lowering on cognition: Results from the HOPE-3 studyJackie Bosch, Martin O'Donnell, Balakumar Swaminathan, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|May 5, 2018
Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of CardiologyGiuseppe M C Rosano, Juan Tamargo, Keld P Kjeldsen, et al.
The New England Journal of Medicine|April 1, 2009
Early versus delayed, provisional eptifibatide in acute coronary syndromesRobert P Giugliano, Jennifer A White, Christoph Bode, et al.
Diabetes Care|June 22, 2025
Cardiovascular Outcomes and Efficacy of the PCSK9 Inhibitor Evolocumab in Individuals With Type 1 Diabetes: Insights From the FOURIER TrialYu Mi Kang, Robert P Giugliano, Xinhui Ran, et al.
JAMA Cardiology|April 30, 2020
An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER TrialBrian A Bergmark, Michelle L O'Donoghue, Sabina A Murphy, et al.
American Heart Journal|December 24, 2018
The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarctionC Michael Gibson, Mathieu Kerneis, Megan K Yee, et al.
Circulation. Heart Failure|April 12, 2013
Left ventricular systolic dysfunction, heart failure, and the risk of stroke and systemic embolism in patients with atrial fibrillation: insights from the ARISTOTLE trialJohn J V McMurray, Justin A Ezekowitz, Basil S Lewis, et al.
Pageof 24

Showing results (191-200 of 240) with videos related to

Sort By:
Pageof 24
Circulation|May 28, 2009
Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial, John H Alexander, Richard C Becker, et al.
European Heart Journal|October 23, 2013
Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trialJohn H Alexander, Renato D Lopes, Laine Thomas, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|June 28, 2021
Subgroup analyses in randomized clinical trials: value and limitations. Review #3 on important aspects of randomized clinical trials in cardiovascular pharmacotherapyHeinz Drexel, Stuart J Pocock, Basil S Lewis, et al.
Neurology|March 1, 2019
Effects of blood pressure and lipid lowering on cognition: Results from the HOPE-3 studyJackie Bosch, Martin O'Donnell, Balakumar Swaminathan, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|May 5, 2018
Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of CardiologyGiuseppe M C Rosano, Juan Tamargo, Keld P Kjeldsen, et al.
The New England Journal of Medicine|April 1, 2009
Early versus delayed, provisional eptifibatide in acute coronary syndromesRobert P Giugliano, Jennifer A White, Christoph Bode, et al.
Diabetes Care|June 22, 2025
Cardiovascular Outcomes and Efficacy of the PCSK9 Inhibitor Evolocumab in Individuals With Type 1 Diabetes: Insights From the FOURIER TrialYu Mi Kang, Robert P Giugliano, Xinhui Ran, et al.
JAMA Cardiology|April 30, 2020
An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER TrialBrian A Bergmark, Michelle L O'Donoghue, Sabina A Murphy, et al.
American Heart Journal|December 24, 2018
The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarctionC Michael Gibson, Mathieu Kerneis, Megan K Yee, et al.
Circulation. Heart Failure|April 12, 2013
Left ventricular systolic dysfunction, heart failure, and the risk of stroke and systemic embolism in patients with atrial fibrillation: insights from the ARISTOTLE trialJohn J V McMurray, Justin A Ezekowitz, Basil S Lewis, et al.
Pageof 24